MUMBAI, India, June 26 -- Intellectual Property India has published a patent application (202641072549 A) filed by Amrita Vishwa Vidyapeetham on June 11, 2026, for Antiproliferative Pyrimidin-Pyrazole Derivatives Effective Against Chronic Myeloid Cancer Cells.
Inventors include Kollur, Shiva Prasad; and Rajashekar, Kv.
The application for the patent was published on June 19, 2026, under issue no. 25/2026.
Abstract: Researchers synthesized and characterized a series of novel methyl-1-(2-((3,5-dimethylphenyl)amino)pyrimidin-4-yl)-1H-pyrazole derivatives using ^1H NMR and mass spectrometry, then evaluated their antiproliferative activity against chronic myeloid leukemia (CML) cell lines, both imatinib-sensitive (K562) and resistant (K562-IM). Among the compounds tested, only compound 5 (bearing a methyl alcohol at the 4-position of the pyrazole ring) and compound 6 (bearing a methyl carboxamide at the same position) showed cytotoxic effects in both cell lines. Compound 6 demonstrated strong cytotoxicity but was also toxic to normal human fibroblasts, limiting its therapeutic potential. In contrast, compound 5 exhibited selective cytotoxicity against both sensitive and resistant CML cells, while sparing normal cells (IC50 50 µM). Furthermore, combining compound 5 with imatinib in resistant cells enhanced cell death compared to imatinib alone. These findings highlight compound 5 as a promising candidate for CML therapy, either alone or in combination, and as a scaffold for new anticancer agents.
Disclaimer: Curated by HT Syndication.
